The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase Ib dose escalation study of JX-594 (TK-vaccinia virus expressing GM-CSF) administered by biweekly intravenous infusion in patients with metastatic, refractory colorectal carcinoma.
Young Suk Park
No relevant relationships to disclose
Jeeyun Lee
No relevant relationships to disclose
Ho Yeong Lim
No relevant relationships to disclose
Jihye Lee
No relevant relationships to disclose
Adina Pelusio
Employment or Leadership Position - Jennerex Biotherapeutics
Stock Ownership - Jennerex Biotherapeutics
James M. Burke
Employment or Leadership Position - Jennerex Biotherapeutics
Stock Ownership - Jennerex Biotherapeutics
Caroline Breitbach
Employment or Leadership Position - Jennerex Biotherapeutics
Stock Ownership - Jennerex Biotherapeutics
David H. Kirn
Employment or Leadership Position - Jennerex Biotherapeutics
Stock Ownership - Jennerex Biotherapeutics